hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06261749, orgStudyIdInfo id: EmgSCAPULA, briefTitle: Analysis of Scapular Musculature Activation During Targeted Abdominal Contraction With Scapular Stabilization Exercises, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-15, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-08, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Hacettepe University, class: OTHER, descriptionModule briefSummary: Muscle activation of the upper trapezius, lower trapezius and serratus anterior muscles will be measured during prone scapular retraction exercises. Then the same exercises will be performed with abdominal contraction using a stabilizer and muscle activity of the same muscles will be measured. A comparison will be made between the two conditions., conditionsModule conditions: Scapula; Increased, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Voluntary Abdominal Contractions, interventions name: Exercise, outcomesModule primaryOutcomes measure: Electromyography, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Hacettepe University, status: RECRUITING, city: Ankara, zip: 06100, country: Turkey, contacts name: İrem Düzgün, Prof, role: CONTACT, phone: +903051577, email: iremduzgun@yahoo.com, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06261736, orgStudyIdInfo id: 2107044-1, briefTitle: The Effectiveness of Prophylactic Antibiotics for Urethral Bulking, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-24, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Atlantic Health System, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to evaluate if prophylactic antibiotics in urethral bulking are effective in reducing postprocedural urinary tract infections., conditionsModule conditions: Stress Urinary Incontinence, conditions: Postoperative Urinary Tract Infection, conditions: Urethral Bulking, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ESTIMATED, armsInterventionsModule interventions name: Prophylactic antibiotics, interventions name: No antibiotics, outcomesModule primaryOutcomes measure: Rate of urinary tract infection (UTI), secondaryOutcomes measure: Rate of postoperative urinary retention, secondaryOutcomes measure: Rates of other postoperative complications, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Atlantic Health, status: RECRUITING, city: Morristown, state: New Jersey, zip: 07960, country: United States, contacts name: Tess Gao, MD, role: CONTACT, phone: 973-971-7267, email: tess.gao@atlantichealth.org, contacts name: Erika Wasenda, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.79677, lon: -74.48154, hasResults: False
protocolSection identificationModule nctId: NCT06261710, orgStudyIdInfo id: EA2_253_23, briefTitle: Intrapartum Ultrasound in Labor: Sonography Only, Few Internal Examinations, acronym: SOFIE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-27, primaryCompletionDateStruct date: 2029-02-01, completionDateStruct date: 2030-02-01, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Larry Hinkson, class: OTHER, descriptionModule briefSummary: This is a prospective, randomized trial to determine whether the use of sonographic parameters during labor results in less intrapartum infection compared to traditional invasive examination. Other secondary outcomes include maternal satisfaction and overall birth outcomes., conditionsModule conditions: Labor Complication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 356, type: ESTIMATED, armsInterventionsModule interventions name: Sonography in labour, outcomesModule primaryOutcomes measure: Maternal Fever Incidence, primaryOutcomes measure: Maternal Tachycardia Incidence, primaryOutcomes measure: Maternal Leucocytosis, primaryOutcomes measure: Uterine tenderness, primaryOutcomes measure: Fetal Tachycardia, primaryOutcomes measure: Foul-smelling amniotic fluid, secondaryOutcomes measure: Average age, secondaryOutcomes measure: Maternal weight, secondaryOutcomes measure: Maternal height, secondaryOutcomes measure: Completed weeks of pregnancy, secondaryOutcomes measure: Previous pregnancy, secondaryOutcomes measure: Incidence of Vaginal Examinations, secondaryOutcomes measure: Incidence of Caesarean section, secondaryOutcomes measure: Incidence of Instrumental Delivery, secondaryOutcomes measure: Incidence of estimated blood loss >1000 ml, secondaryOutcomes measure: Incidence of antibiotics usage, secondaryOutcomes measure: Incidence of Neonatal Admission, secondaryOutcomes measure: Neonatal weight, secondaryOutcomes measure: Maternal Satisfaction Scores, otherOutcomes measure: Incidence of Chorioamnionitis on Placenta Histologie, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Charité University Hospital, status: RECRUITING, city: Berlin, country: Germany, contacts name: Larry Hinkson, FRCOG, role: CONTACT, geoPoint lat: 52.52437, lon: 13.41053, hasResults: False
protocolSection identificationModule nctId: NCT06261697, orgStudyIdInfo id: P.T.REC/012/004876, briefTitle: Relationship Between Smartphone Addiction and Temporomandibular Joint Disorders Among Adults in Egypt., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-20, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: Cross sectional study to investigate the relation between Smartphone addiction and temporomandibular disorders among youth population in Egypt. An online- based questionnaire study. A 296 participants who are Egyptians with age between18 and 35 years old without prior neck and upper extremity related diseases, orofacial trauma or surgeries, history of rheumatoid arthritis or congenital musculoskeletal problems. An online- based questionnaire will be sent through different social media platforms, it will include three screens, the first includes the consent form, the second includes the demographic data (year of birth, current educational status, gender and geographic information ), and the third page includes questionnaires., conditionsModule conditions: Temporomandibular Disorders, conditions: Smartphone Addiction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: PROSPECTIVE, enrollmentInfo count: 296, type: ESTIMATED, armsInterventionsModule interventions name: A web based survey, outcomesModule primaryOutcomes measure: Fonseca Anamnestic Index (FAI) questionnaire, primaryOutcomes measure: Smartphone Addiction Scale-Short version (SAS-SV) questionnaire, primaryOutcomes measure: Patient Health Questionnaire (PHQ), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06261684, orgStudyIdInfo id: MS-259-2023, briefTitle: Intralesional Acyclovir Versus Cryotherapy in the Treatment of Plantar Warts. A Randomized Controlled Trial., statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-10-01, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: The goal of this prospective randomized controlled study is to study the safety and efficacy of intralesional acyclovir compared to cryotherapy in plantar warts. The main questions needed to be answered are:1. Is Intralesional acyclovir safe for plantar warts?2. Is Intralesional acyclovir more efficient in treating plantar warts compared to cryotherapy?, conditionsModule conditions: Plantar Wart, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 92, type: ESTIMATED, armsInterventionsModule interventions name: Intralesional Acyclovir, interventions name: Cryotherapy, outcomesModule primaryOutcomes measure: Cure rate, primaryOutcomes measure: Recurrence rate, primaryOutcomes measure: Patient satisfaction score, secondaryOutcomes measure: Correlation of treatment with number of ipsilateral warts, secondaryOutcomes measure: Correlation of treatment with age, secondaryOutcomes measure: Correlation of treatment with gender, secondaryOutcomes measure: Correlation of treatment with size of the wart, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cairo University Hospital, status: RECRUITING, city: Cairo, country: Egypt, contacts name: Basant Helal, MRCP, role: CONTACT, contacts name: Shahira Ramadan, Professor, role: PRINCIPAL_INVESTIGATOR, contacts name: Yousra Azzazi, Lecturer, role: SUB_INVESTIGATOR, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06261671, orgStudyIdInfo id: 2312-ABU-028-VF, briefTitle: Effect of Antioxydant-enriched Media on Blastocyst Euploidy Rates., acronym: GX, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: ART Fertility Clinics LLC, class: OTHER, descriptionModule briefSummary: One of the most sensible factors in IVF culture conditions is the susceptibility of gametes and embryos to an induced increase in reactive oxidative species (ROS) caused by the artificial environment. This study aims to evaluate the impact of using antioxidant-supplemented media during culture to evaluate embryo ploidy rates in a prospective randomized trial using sibling oocytes., conditionsModule conditions: Infertility, conditions: In Vitro Fertilization, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A randomization list (indicating Gx Media Vitrolife or GT Coopersurgical) will be used to verify to which group the first half of oocytes will be allocated to. In case an odd number of oocytes is present, one extra oocyte is allocated to the group as indicated by the randomization list., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: antioxidants-enriched culture medium (Gx), outcomesModule primaryOutcomes measure: Blastocyst ploidy is determined after a biopsy of trophectoderm cells, taken from the blastocyst on day 5, 6 or 7 from development. The following outcomes are possible: • Normal • Abnormal • No result/Inconclusive • Low or high Mosaic, secondaryOutcomes measure: Cycle ploidy rate: the number of euploid embryos in the group Blastocyst quality at the time of biopsy based on modified Gardner's criteria. Usable blastocyst rate per group and per day of biopsy (day 5, 6, 7), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 43 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06261658, orgStudyIdInfo id: TESOVA2022, briefTitle: Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma, acronym: TESOVA2022, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-12-29, completionDateStruct date: 2033-12-29, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: IRCCS Azienda Ospedaliero-Universitaria di Bologna, class: OTHER, descriptionModule briefSummary: The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue., conditionsModule conditions: Cryopreservation, conditions: Ovary Injury, conditions: Infertility, Female, conditions: Menopause Ovarian Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Cryopreserved Ovarian Tissue Reimplantation, outcomesModule primaryOutcomes measure: Safety of Cryopreserved ovarian tissue transplantation Using Platelet-enriched Autologous Plasma, secondaryOutcomes measure: Effectiveness of Cryopreserved ovarian tissue transplantation Using Platelet-enriched Autologous Plasma, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Diego Raimondo, status: RECRUITING, city: Bologna, state: BO, zip: 40138, country: Italy, contacts name: Diego Raimondo, MD, role: CONTACT, phone: 0512144389, phoneExt: 0039, email: die.raimondo@gmail.com, contacts name: Renato Seracchioli, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Diego Raimondo, MD, role: SUB_INVESTIGATOR, contacts name: Rossella Vicenti, PhD, role: SUB_INVESTIGATOR, contacts name: Valentina Magnani, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 44.49381, lon: 11.33875, hasResults: False
protocolSection identificationModule nctId: NCT06261619, orgStudyIdInfo id: 2079951, briefTitle: Superiority Trial Between Sotair® Device Attached to Manual Resuscitator Versus Ventilation Alone, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-19, primaryCompletionDateStruct date: 2025-01-31, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Rhode Island Hospital, class: OTHER, descriptionModule briefSummary: Effective respiratory ventilation is achieved by moving the right amount of air to and out of the lungs while keeping the pressures at a safe level. A disposable safety device, Adult Sotair®, was created to improve manual ventilation delivery. In this superiority study, the investigators will perform two-group cross over randomized design to test the superiority of the Adult Sotair® device compared to manual ventilation alone., conditionsModule conditions: Airway Management, conditions: Respiration, Artificial, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Study Design: A superiority trial; a single two-group cross over randomized trial., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: The care provider will not know the recorded lung function recordings., whoMasked: PARTICIPANT, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Adult Sotair Device, outcomesModule primaryOutcomes measure: Peak airway pressure, secondaryOutcomes measure: Tidal volume, secondaryOutcomes measure: Airflow, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Rhode Island Hospital, status: RECRUITING, city: Providence, state: Rhode Island, zip: 02903, country: United States, contacts name: Mark Kendall, MD, role: CONTACT, phone: 401-444-5172, email: mark.kendall@lifespan.org, geoPoint lat: 41.82399, lon: -71.41283, hasResults: False
protocolSection identificationModule nctId: NCT06261606, orgStudyIdInfo id: 4020286, briefTitle: Feasibility of a Multifaceted Program to Reduce Cardiovascular Complications of Air Pollution, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-28, primaryCompletionDateStruct date: 2024-03, completionDateStruct date: 2024-03, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Parham Sadeghipour, class: OTHER, descriptionModule briefSummary: The main goal of this clinical trial is to evaluate the feasibility of conducting a large-scale clinical trial testing a program containing several aspects for reducing the effects of air pollution on cardiovascular health (which is named the hybrid program hereafter) in adult patients (18 years or older) with atherosclerotic cardiovascular disease. Furthermore, we seek to answer how much patients adhere to and are satisfied with implementing the hybrid program, and what problems executing this program will bring for patients., conditionsModule conditions: Atherosclerosis, conditions: Coronary Artery Disease, conditions: Peripheral Arterial Disease, conditions: Ischemic Stroke, conditions: Carotid Artery Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants undergo permuted block randomization with block sizes of four via a web-based system will be used for the study, in a 1:1 ratio between the hybrid strategy or control arms., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Hybrid strategy, outcomesModule primaryOutcomes measure: Feasibility of conducting the trial, secondaryOutcomes measure: Adherence to the individual components of the hybrid strategy, secondaryOutcomes measure: Patient satisfaction with the hybrid strategy, secondaryOutcomes measure: Any potential adverse events in intervention and control groups during the 30-day follow-up, otherOutcomes measure: Change in the health-related quality of life, otherOutcomes measure: Change in the level of anxiety, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Rajaie Cardiovascular Medical and Research Center, status: RECRUITING, city: Tehran, zip: 1995614331, country: Iran, Islamic Republic of, contacts name: Parham Sadeghipour, MD, role: CONTACT, phone: +98 21 2392 2092, email: psadeghipour@rhc.ac.ir, geoPoint lat: 35.69439, lon: 51.42151, hasResults: False
protocolSection identificationModule nctId: NCT06261580, orgStudyIdInfo id: TP-CLN-100502, briefTitle: Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-07-28, primaryCompletionDateStruct date: 2021-10-25, completionDateStruct date: 2021-10-25, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Haemonetics Corporation, class: INDUSTRY, collaborators name: Machaon Diagnostics, collaborators name: ClinStatDevice, descriptionModule briefSummary: This trial holds minimal risk to the trial volunteers and consists of obtaining whole blood via venipuncture to perform coagulation parameter measurements to define a Normal Reference Range.Written consent to participate in the study will be obtained prior to volunteer screening per site procedures., conditionsModule conditions: Healthy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 181, type: ACTUAL, armsInterventionsModule interventions name: TEG 6s Citrated K, KH, RTH, and FFH Cartridge, interventions name: Clauss Fibrinogen, outcomesModule primaryOutcomes measure: CK-MA TEG Parameter, primaryOutcomes measure: CK-R TEG Parameter, primaryOutcomes measure: CKH-MA TEG Parameter, primaryOutcomes measure: CKH-R TEG Parameter, primaryOutcomes measure: CKH-LY30 TEG Parameter, primaryOutcomes measure: CRTH-MA TEG Parameter, primaryOutcomes measure: CFFH-MA TEG Parameter, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Machaon Diagnostics, city: Oakland, state: California, zip: 94609, country: United States, geoPoint lat: 37.80437, lon: -122.2708, locations facility: Cardiovascular Research Institute - Loyola University Chicago Health Sciences, city: Maywood, state: Illinois, zip: 60153, country: United States, geoPoint lat: 41.8792, lon: -87.84312, locations facility: Louisiana Coagulation / Machaon Division, city: New Orleans, state: Louisiana, zip: 70118, country: United States, geoPoint lat: 29.95465, lon: -90.07507, hasResults: False
protocolSection identificationModule nctId: NCT06261554, orgStudyIdInfo id: Low-dose sesame OIT, briefTitle: Efficacy and Safety of Low-dose Sesame Oral Immunotherapy in Pediatric Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-03-01, completionDateStruct date: 2027-03-01, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Medical University of Warsaw, class: OTHER, descriptionModule briefSummary: It is a randomized, single-center, controlled trial to evaluate the effectiveness of oral immunotherapy with low-dose sesame protein compared with standard treatment (elimination diet) in patients with sesame allergy., conditionsModule conditions: Food Allergy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 39, type: ESTIMATED, armsInterventionsModule interventions name: Dietary Supplement: Low dose OIT, outcomesModule primaryOutcomes measure: Tolerance of sesame, secondaryOutcomes measure: Adverse event, secondaryOutcomes measure: Laboratory data, secondaryOutcomes measure: Basophil activation test, secondaryOutcomes measure: Skin prick test (SPT), secondaryOutcomes measure: Desensitization dose, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Medical University of Warsaw, status: RECRUITING, city: Warsaw, state: Mazowieckie, zip: 02-091, country: Poland, contacts name: Katarzyna Grzela, PhD, MD, role: CONTACT, phone: +48 22 3179431, email: katarzyna.grzela@wum.edu.pl, geoPoint lat: 52.22977, lon: 21.01178, hasResults: False